| 11/16/2026 8:52 AM | Polar Capital Holdings Plc (1837309) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G | |
| 11/09/2026 3:31 PM | Xenon Pharmaceuticals (1582313) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 11/09/2026 3:37 PM | Xenon Pharmaceuticals (1582313) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 11/06/2026 10:07 AM | T. Rowe Price Investment Management, Inc. (1897612) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G/A | |
| 11/06/2026 9:58 AM | T. Rowe Price Investment Management, Inc. (1897612) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G | |
| 11/05/2026 12:29 PM | FMR LLC (315066) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G/A | |
| 10/16/2026 7:22 PM | Kelly Thomas Patrick (1410514) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2026 8:19 AM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2026 8:20 AM | Kelly Thomas Patrick (1410514) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/03/2026 7:26 PM | Svoronos Dawn (1574579) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/31/2026 8:59 PM | KENNEY CHRISTOPHER JOHN (1880129) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for XENE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
| 08/13/2026 3:30 PM | GANNON STEVEN (1643085) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/13/2026 3:33 PM | GANNON STEVEN (1643085) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/07/2026 10:04 AM | FMR LLC (315066) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G/A | |
| 08/06/2026 9:43 AM | FMR LLC (315066) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G/A | |
| 06/08/2026 8:19 PM | Cannon Gillian (1833910) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 8:19 PM | PATOU GARY (1283535) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/05/2026 3:32 PM | PATOU GARY (1283535) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/05/2026 3:32 PM | Cannon Gillian (1833910) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/03/2026 8:03 PM | Svoronos Dawn (1574579) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 8:03 PM | Cannon Gillian (1833910) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 8:04 PM | GANNON STEVEN (1643085) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 8:04 PM | GAROFALO ELIZABETH A. (1826361) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 8:04 PM | Gover Justin D. (1754129) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 8:04 PM | Machado Patrick (1311210) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 8:04 PM | PATOU GARY (1283535) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 3:17 PM | Xenon Pharmaceuticals (1582313) Filer | Form S-8 POS | |
| 06/03/2026 3:20 PM | Xenon Pharmaceuticals (1582313) Filer | Form S-8 POS | |
| 06/03/2026 3:21 PM | Xenon Pharmaceuticals (1582313) Filer | Form S-8 POS | |
| 06/03/2026 3:02 PM | Xenon Pharmaceuticals (1582313) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2026 3:06 PM | Xenon Pharmaceuticals (1582313) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 05/15/2026 10:23 AM | JANUS HENDERSON GROUP PLC (1274173) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G/A | |
| 05/15/2026 7:17 AM | Avoro Capital Advisors LLC (1633313) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G/A | |
| 05/15/2026 6:06 AM | DRIEHAUS CAPITAL MANAGEMENT LLC (938206) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G/A | |
| 05/13/2026 8:40 PM | GANNON STEVEN (1643085) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/07/2026 3:35 PM | Xenon Pharmaceuticals (1582313) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/07/2026 3:02 PM | Xenon Pharmaceuticals (1582313) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/22/2026 3:02 PM | Xenon Pharmaceuticals (1582313) Filer | Form DEF 14A | |
| 04/22/2026 3:04 PM | Xenon Pharmaceuticals (1582313) Filer | Form DEFA14A | |
| 04/22/2026 3:05 PM | Xenon Pharmaceuticals (1582313) Filer | Form ARS | |
| 04/13/2026 3:01 PM | Xenon Pharmaceuticals (1582313) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Beyond NVDA: The World’s Next #1 Company? (Ad) This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's.
A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth."
Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all. Discover the small-cap company at the center of this tech revolution. |
| 04/13/2026 3:04 PM | Xenon Pharmaceuticals (1582313) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/13/2026 7:16 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/13/2026 7:16 PM | DiFabio Andrea (1692506) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/13/2026 7:16 PM | KENNEY CHRISTOPHER JOHN (1880129) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/13/2026 6:49 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/13/2026 6:50 PM | DiFabio Andrea (1692506) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/13/2026 6:51 PM | KENNEY CHRISTOPHER JOHN (1880129) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/12/2026 3:17 PM | Xenon Pharmaceuticals (1582313) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/11/2026 6:20 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/11/2026 6:20 PM | DiFabio Andrea (1692506) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/11/2026 6:21 PM | KENNEY CHRISTOPHER JOHN (1880129) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/10/2026 8:23 PM | Xenon Pharmaceuticals (1582313) Subject | Form FWP | |
| 03/10/2026 7:57 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/10/2026 7:58 PM | KENNEY CHRISTOPHER JOHN (1880129) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/10/2026 8:01 PM | DiFabio Andrea (1692506) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/09/2026 6:36 AM | Xenon Pharmaceuticals (1582313) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/26/2026 3:12 PM | Xenon Pharmaceuticals (1582313) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 02/26/2026 3:03 PM | Xenon Pharmaceuticals (1582313) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/10/2026 10:23 AM | WELLINGTON MANAGEMENT GROUP LLP (902219) Filed by Xenon Pharmaceuticals (1582313) Subject | Form SCHEDULE 13G | |
| 01/09/2026 5:51 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 5:52 PM | DiFabio Andrea (1692506) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 5:53 PM | Cline Darren S (1633639) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/09/2026 5:54 PM | KENNEY CHRISTOPHER JOHN (1880129) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 5:49 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/02/2026 5:47 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/09/2025 6:40 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/08/2025 4:10 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/05/2025 4:54 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/03/2025 7:20 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/01/2025 6:36 PM | MORTIMER IAN (1619961) Reporting Xenon Pharmaceuticals (1582313) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |